Nicholas Goldner

Nicholas Goldner is the Co-Founder and Chief Executive Officer of resistanceBio, a precision medicine biotechnology company based in the United States. As a technical founder holding a PhD in Molecular Cell Biology, he specializes in researching how living cells adapt and ultimately thrive within highly hostile environments. At resistanceBio, Goldner applies this complex biological framework to develop novel therapeutic solutions specifically aimed at overcoming cancer treatment resistance. He translates his scientific research into broader operational strategies, utilizing cellular behavior models to predict the success of early-stage projects and ventures facing significant adversity. His ongoing work in the oncology sector led to his selection as a featured speaker at the 2023 Precision Medicine World Conference in Silicon Valley. Goldner currently focuses on building specialized biotech enterprises that leverage molecular biology to address critical vulnerabilities in modern therapeutic development pipelines.